EVALUATION OF VASOSTATIN, AN INHIBITOR OF ANGIOGENESIS, AS A POTENTIAL CANCER THERAPEUTIC.

Notice Date

November 8, 2001

Contracting Office

NIH/TDCB, 6120 Executive Blvd., Suite 450, Rockville, MD 20852

ZIP Code

20852

E-Mail Address

Click here to send a message to the CRADA point of (FrisbieS@otd.nci.nih.gov)

Description

National Cancer Institute Technology Transfer Branch CRADA Opportunity Announcement Summary: The National Cancer Institute (NCI) is currently seeking a Collaborator for a Cooperative Research and Development Agreement (CRADA) to work with investigators in the Experimental Transplantation and Immunology Branch to study vasostatin, an inhibitor of angiogenesis, and evaluate its potential as a cancer therapeutic. Proposed NCI Contribution: Expertise in the field of angiogenesis and in the biological and biochemical properties of vasostatin, a calreticulin fragment that inhibits endothelial cell proliferation in vitro, angiogenesis and tumor growth in vivo. NCI would provide the bacteria expressing the active molecule, active fragments and inactive mutants, and methods for purification. NCI would also provide information on the surface receptor for the molecule and its signaling as this information becomes available through continuing laboratory investigation. Proposed CRADA Collaborator Contribution: The CRADA Collaborator would provide highly purified protein produced under GLP conditions to support the NCI laboratory. Collaborator would work with the NCI laboratory to further develop the drug as a cancer therapeutic for human use. This would include preclinical and laboratory studies designed to identify the cell surface receptor for vasostatin and clarifying its downstream signaling, as well as studies in pre-clinical animal models. Proposed Joint Contribution: NCI and the Collaborator will jointly design a CRADA Research Plan and will jointly interpret the data generated under the research plan. Selection Criteria for Choosing the CRADA Collaborator May Include: 1. A demonstrated background and expertise in recombinant protein manufacturing. 2. A demonstrated record of success in the commercial development and production of products related to this area of technology. 3. The demonstration of adequate resources to assist in this collaboration and to perform the research and development necessary for commercialization of the resulting inventions. 4. The willingness to commit best effort and demonstrated resources to the research and development of vasostatin and/or one or more of its fragments. 5. The level of financial and staffing support the CRADA Collaborator will provide for CRADA-related activities. 6. The willingness to cooperate with the NCI in the timely publication of research results. 7. The agreement to be bound by the appropriate Department of Health and Human Services (DHHS) regulations relating to human subject research and to all Public Health Service (PHS) policies relating to the use and care of laboratory animals. 8. The willingness to accept the legal provisions and language of the CRADA. These provisions govern the distribution of future patent rights to CRADA inventions. Generally, the rights of ownership are retained by the organization that is the employer of the inventor with (1) the grant of a license for research and other Government purposes to the Government when the CRADA Collaborator's employee is the sole inventor, or (2) the grant of an option to elect an exclusive or nonexclusive license to the CRADA Collaborator when the Government employee is the sole inventor. Response Procedure: Interested parties should notify the Technology Transfer Branch of the NCI in writing of their interest in the CRADA collaboration no later than December 6, 2001. The written notice should briefly address the selection criteria listed above. Contact Information: CRADA Contact: Suzanne M. Frisbie, Ph.D. 6120 Executive Boulevard, Suite 450 Rockville, Maryland 20852 Phone: 301-496-0477 Fax: 301-402-2117 Email: FrisbieS@otd.nci.nih.gov

Web Link

Click here to view the standard NIH CRADA document. (http://ttb.nci.nih.gov/forms.html)

Record

Loren Data Corp. 20011113/SPMSC009.HTM (W-312 SN5126H7)